Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
731
resultados
Última actualización
15/04/2026 [07:21:00]
Resultados 425 a 450 de 731
Resumen de: WO2026043873A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided. For instance, the formulations, kits, and vaccines can induce an immune response in an animal against a Salmonella infection in which the Salmonella infection is caused by more than one Salmonella group bacterium (e.g., a Group B bacterium, a Group C bacterium, and a Group D bacterium).
Resumen de: WO2026044176A1
The invention provides anti-enterotoxigenic E. coli (ETEC) adhesin protein antibodies and methods of using the same. One embodiment is an isolated antibody that binds ETEC coli surface antigen 3 (CS3) protein and ETEC coli surface antigen 6 (CS6) protein, wherein the antibody comprises a CS3/CS6 VHH binding domain comprising the following complementary-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of GFTFEDYA (SEQ ID NO: 19); (b) a CDR-H2 comprising the amino acid sequence of INMSDGST (SEQ ID NO: 20); and (c) a CDR-H3 comprising the amino acid sequence of AANLTGPSGGGLPGYNYDY (SEQ ID NO: 21). Also disclosed are antibodies comprising said CS3/CS6 binding VHH and a binding domain capable of binding to an ETEC adhesin protein selected from colonization factor antigen I adhesin subunit E (CfaE), coli surface antigen 1 (CS1), coli surface antigen 4 (CS4), coli surface antigen 14 (CS14), coli surface antigen 17 (CS17), coli surface antigen 19 (CS19), and coli surface antigen 2 (CS2).
Resumen de: WO2024218333A1
The present invention relates to compounds of formula (la) that block invasion-associated pathogenicity of Salmonella Typhimurium by inhibiting the activity of the transcription factor HilD. These compounds are useful in the treatment or prophylaxis of Salmonella infections (salmonellosis).
Resumen de: EP4699617A1
A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA/I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G/ L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and/or Shigella spp.
Resumen de: CN121555356A
The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.
Resumen de: CN121554580A
本发明公开了鼠疫抗体Fm3及其应用。本发明为本领域提供了一种全新的靶向鼠疫菌F1蛋白的鼠源单克隆抗体，所述抗体能够有效中和鼠疫强毒株和耐药株，具有较好的亲和力和特异性，能够有效抵抗致死剂量的强毒株和耐药株的攻击。本发明为本领域开发鼠疫强毒株和耐药株的治疗药物提供了新策略，具有良好的应用前景。
Resumen de: WO2025021695A1
The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.
Resumen de: CN121555461A
The invention discloses a high-density fermentation process of salmonella bacteriophage RNA polymerase, and belongs to the technical field of salmonella. The invention relates to a high-density fermentation process of salmonella phage RNA polymerase. The high-density fermentation process comprises the following steps: S1, preparing a seed solution; s2, seed amplification culture; s3, performing high-density fermentation; s4, performing induced expression; s5, enzyme extraction and purification. The method solves the problems that in the prior art, the culture period completely depends on the splitting speed of the host bacteria, if the period needs to be shortened, the initial bacteriophage infection complex number can only be increased, however, the host bacteria are split too early, and the titer is further reduced. By optimizing a culture medium and a material supplementing strategy, the wet weight of thalli is greatly increased, the enzyme yield per unit fermentation volume is remarkably increased, the enzyme activity ratio and purity of the thalli are increased, the fermentation period is effectively shortened, the production efficiency is improved, and a short-period medium yield mode or a long-period high yield mode can be flexibly switched to meet diversified production requirements.
Resumen de: WO2026039487A1
The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.
Resumen de: US20260048109A1
Provided herein are methods for vaccinating a subject against a Salmonella species, including typhoidal and non-typhoidal Salmonella species and serovars thereof with an Escherichia coli J5 dLOS/OMP vaccine. The vaccine is cross-reactive with the lipopolysaccharide conserved inner core region of the Salmonella species and cross-protective with the non-typhoidal Salmonella species. Vaccination reduces the likelihood of or prevents the onset of a salmonella infection. Also provided is a method of immunizing against antimicrobial resistant Salmonella species by complementing the J5 dLOS/OMP vaccine with a Salmonella species-specific vaccine.
Resumen de: US20260048111A1
The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.
Resumen de: US20260048107A1
A vaccine is disclosed which comprises a pharmaceutically acceptable carrier and Gramnegative bacteria, genetically modified to express: at least one disease-associated antigen, linked to a signal sequence belonging to a type II secretion system; and the at least one disease-associated antigen linked to a signal sequence belonging to a type III secretion system. Uses thereof are also disclosed.
Resumen de: CN121534203A
The invention provides a montmorillonite-based oral intestinal in-situ fermentation system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the system, montmorillonite is taken as a carrier, metabolic substrates such as tryptophan and lactulose are loaded between montmorillonite layers through cation replacement, and substrate-related microorganisms such as enterococcus faecalis are adsorbed by utilizing electrostatic interaction, so that an MMT-Bacc-TL complex is obtained. The water impermeability of the montmorillonite endows the system with the ability to resist the severe environment of the gastrointestinal tract, the mucous membrane adhesion characteristic realizes the long-acting retention of the intestinal tract, and beneficial metabolites such as indole and lactic acid are permanently and efficiently synthesized in the intestinal tract by continuously releasing a substrate and forming a bacterial biofilm. The system can remarkably regulate intestinal flora balance, inhibit intestinal inflammation and enhance intestinal barrier integrity, shows curative effects superior to those of existing therapies in diseases such as salmonella typhimurium induced enteritis and candida albicans infection related colitis, is high in oral bioavailability, and can be widely applied to treatment of salmonella typhimurium induced enteritis and candida albicans infection related colitis. And a new effective m
Resumen de: CN121538126A
The invention discloses a Rongchang pig source ZH30 strain and application thereof, and belongs to the technical field of agricultural livestock feed additives. The ZH30 strain provided by the invention has bacteriostatic activity on a plurality of common pig pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella typhimurium, salmonella pullorum and enterococcus faecalis, is wide in antibacterial spectrum, and is beneficial to reducing the load of pathogenic bacteria in intestinal tracts of pigs. Meanwhile, the ZH30 strain is sensitive to streptomycin, gentamicin and ampicillin, infectious microbe pollution can be conveniently controlled through a conventional antibiotic means in the fermentation and preparation production process, and meanwhile the drug resistance spreading risk is reduced. As a functional strain of a probiotic preparation for pigs, the ZH30 strain disclosed by the invention can improve the intestinal health of pigs and improve the mechanical barrier integrity of the intestinal tracts, has potential application values of reducing the diarrhea risk of piglets and improving the feed utilization rate and the production performance, and is of great significance to the development of animal husbandry and feed industry.
Resumen de: WO2025021712A1
The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.
Resumen de: EP4650361A1
The present invention relates to an arginine fluorescent optical probe. Specifically, the present invention provides an arginine-sensitive polypeptide, wherein the arginine-sensitive polypeptide is a variant of an arginine binding protein, and formula (1) thereof has a sequence as shown in SEQ ID NO: 1 and has mutations at one, two, or three or more sites selected from the following. Compared with a probe formed by a wild arginine-sensitive polypeptide, the fluorescent probe of the present invention has greater dynamic changes in fluorescence and better specificity, and can be used for the high-throughput and quantitative detection of arginine inside and outside of cells.
Resumen de: CN121538185A
The invention discloses a salmonella bacteriophage cocktail composition targeting three receptor binding sites and application thereof, the salmonella bacteriophage cocktail composition comprises a salmonella outer membrane protein ompc and lipopolysaccharide targeting BPSBW1, a salmonella outer membrane protein btuB targeting BPSEW7-1 and a salmonella lipopolysaccharide targeting Phi PhSELC which are all preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO: M 20251569, CCTCC NO: M 20251570 and CCTCC NO: M 20251568, the salmonella outer membrane protein ompc and lipopolysaccharide targeting Phi PhSELC is preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO: M 20251568, the salmonella the preservation date is July 11, 2025. The bacteriophage combination targeting three receptor binding sites has broad-spectrum and efficient salmonella splitting capacity, provides a bacteriophage source for preventing and treating salmonella in culture and food processing links, and can be used as a green and environment-friendly product or means for preventing and treating salmonella.
Resumen de: CN121540789A
The invention belongs to the technical field of biosensing analysis and food safety detection, and particularly relates to a CRISPR/Cas12a-based double-layer microfluidic electrochemical biosensor as well as a preparation method and application thereof. A single-walled carbon nanohorn-polypyrrole-gold nanoparticle compound modified electrode is constructed and integrated with an electrochemical detection system, then the electrochemical detection system and a micro-fluidic chip are integrated to obtain the double-layer micro-fluidic electrochemical biosensor, targeted detection of different pathogenic bacteria can be achieved by replacing crRNA, and the electrochemical biosensor has the advantages of high specificity, high sensitivity, high sensitivity and the like. Good universality and expansibility are realized; the biosensor can rapidly and sensitively detect staphylococcus aureus and salmonella in dairy products, the detection ranges are 1.06 * 10 < 1 >-1.06 * 10 < 7 > CFU/mL and 1.04 * 10 < 1 >-1.04 * 10 < 7 > CFU/mL respectively, the detection limits are as low as 3 CFU/mL, and the biosensor has good practicability.
Resumen de: CN121522155A
本发明公开了一种巴氏杀菌乳中沙门氏菌的检测方法，涉及食品检测技术领域，本发明通过构建铂基聚合物纳米酶复合探针，结合免疫磁珠分离与信号放大策略，提出了一种适用于巴氏杀菌乳中沙门氏菌的一步法快速高灵敏检测方法。本发明基于铂基聚合物纳米酶优异的类过氧化物酶活性，该复合探针可在低浓度目标菌存在下催化显色底物产生强信号放大效应，实现在巴氏杀菌乳基质中对沙门氏菌的低至10CFU/mL的检测限，较传统培养法及部分现有免疫学方法灵敏度提升一至两个数量级，显著增强了低污染水平沙门氏菌的检出能力。
Resumen de: CN121517555A
本发明公开了一种结合K88ac的特异性纳米抗体、制备方法及其应用，属于生物工程技术领域。所述纳米抗体命名为NBK88，其氨基酸序列如SEQ ID NO:2所示。同时公开了其编码基因、重组表达载体、宿主细胞及制备方法与应用。本发明公开的纳米抗体NBK88对K88ac抗原具有纳摩尔级的高亲和力（KD=1.733×10‑7 M），使其在识别过程中兼具高灵敏度与高特异性；基于该抗体构建的检测方法能够有效捕获样本中微量K88ac蛋白，即使在低菌量或复杂样本中也可实现早期准确检测，显著降低检测限；同时，其与K88ac的结合高度特异，在K88阳性与阴性菌株间呈现统计学显著差异，可有效避免与其他ETEC血清型或肠道菌群的交叉反应，杜绝假阳性，确保检测结果精准可靠。
Resumen de: CN121518528A
The invention discloses recombinant lactobacillus casei for expressing sialyltransferase ST6GALNAC1, and belongs to the technical field of genetic engineering and microorganisms. The recombinant bacterium is obtained by cloning an ST6GALNAC1 gene to a pPG612 vector and electrically transforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucoprotein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38/MAPK inflammation pathway and regulate an intestinal flora structure, so that intestinal injury and systemic inflammatory response caused by salmonella are effectively relieved. The invention provides a strain basis and technical support for developing a novel oral microecological preparation.
Resumen de: CN121517526A
本发明属于生物技术领域，涉及一种沙门菌靶向抗菌肽Yisi‑1及其应用。所述靶向抗菌肽Yisi‑1的氨基酸序列为丙氨酸‑异亮氨酸‑赖氨酸‑甘氨酸‑缬氨酸‑赖氨酸‑丙氨酸‑甘氨酸‑异亮氨酸‑精氨酸‑亮氨酸‑甘氨酸‑赖氨酸‑赖氨酸‑甘氨酸‑亮氨酸‑精氨酸‑丙氨酸，该靶向抗菌肽Yisi‑1的分子量为1836.3Da，等电点为12.1，带6个正电荷，两亲性高，对金黄色葡萄球菌、大肠杆菌、奇异变形杆菌、绿脓杆菌、白色念珠菌等均没有抑菌活性，仅对沙门菌具有抑菌活性，对鸡红细胞具有较低的溶血性。本发明的靶向抗菌肽Yisi‑1有望成为一种新的抗生素替代物，将在预防、诊断、治疗和鉴定沙门菌及其感染中具有良好的应用前景。
Resumen de: CN121522153A
本发明公开了肠道菌群代谢物水杨酸作为大肠杆菌性犊牛腹泻预测标志物的应用。通过非靶向代谢组学技术从腹泻犊牛粪便中筛选出显著上调的代谢物水杨酸，并在一组新的独立样本中，通过ELISA试验验证了腹泻组犊牛粪便水杨酸浓度显著高于健康组。ROC曲线分析表明，SA预测大肠杆菌性犊牛腹泻的曲线下面积（AUC）为0.8148，具有良好的预测能力。本发明提供了一种非侵入性、廉价、快速且特异性强的预测方法，可用于大肠杆菌性犊牛腹泻的早期预警和辅助诊断，对指导临床精准用药、降低犊牛死亡率具有重要意义。
Resumen de: CN121517554A
本发明公开了鼠疫抗体Fm25及其应用，所述鼠疫抗体Fm25是一种靶向鼠疫菌F1蛋白的抗体，其重链可变区中的HCDR1‑3分别如SEQ ID NO:1‑3所示，轻链可变区中的LCDR1‑3分别如SEQ ID NO:5‑7所示，其对F1蛋白具有较高的结合活性和较好的结合特异性，能够用于鼠疫菌感染的检测和治疗中，对防控鼠疫具有重要意义。
Nº publicación: EP4692334A1 11/02/2026
Solicitante:
KANEKA CORP [JP]
RAKUNO GAKUEN UNIV [JP]
MITSUI BUSSAN [JP]
Kaneka Corporation,
Rakuno Gakuen University,
Mitsui & Co., Ltd
Resumen de: EP4692334A1
An aim of the present invention is to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella. The present invention is a bacteriophage with bacteriolytic activity against bacteria of the genus Salmonella, in which the bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence.
BOPI
Sede Electrónica
